Eton secures US patent for diabetes insipidus treatment
Desmopressin is approved in various forms, but these do not meet the paediatric need for precise, titratable and small doses.
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange ...